William Blair

The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.

The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.

Wall Street analysts are bullish on the firm's cell selection platform technology, which could find a total addressable market of more than $20 billion.

The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.

Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.

The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.

The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

Canaccord and William Blair also increased their price targets on  Quidel's shares, following its acquisition of certain Alere assets and assays.